Study title: Clinical Performance of PET/CT in Evaluation of Cancer: Additional Value for Diagnostic Imaging and Patient ManagementRachel Bar-Shalom, MD1; Nikolai Yefremov, MD1; Ludmila Guralnik, MD2; Diana Gaitini, MD2,3; Alex Frenkel, DSc1; Abraham Kuten, MD3,4; Hernan Altman, MBA5; Zohar Keidar, MD, PhD1; and Ora Israel, MD1,3. THE JOURNAL OF NUCLEAR MEDICINE • Vol. 44 • No. 8 • August 2003
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Diagnosis | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: Steripet | |||||
| ATC code: | |||||
| Document link: bar-shalom-2003.pdf | |||||
| Document date: 2014-11-18 | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |